San Francisco, CA (Press Release) – Nektar Thera­peutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clin­i­cal study eval­u­ating NKTR-255, an interleukin-15 (IL-15) re­cep­tor agonist, as mono­therapy for patients with re­lapsed or re­frac­tory non-Hodgkin lym­phoma (NHL) or multiple myeloma (MM). The study will also combine NKTR-255 with multiple targeted anti­bodies, that function through an anti­body-dependent cell-mediated cyto­tox­icity (ADCC) mech­a­nism, to eval­u­ate the safety and efficacy in adults with re­lapsed or re­frac­tory MM. NKTR-255 is designed to activate the IL-15 path­way and ex­pand functionally superior natural killer (NK) cells and promote …